Filing Flows

Filing Flows › Comparisons › CTXR vs VTGN

Citius Pharmaceuticals vs Vistagen Therapeutics: CTXR and VTGN compared

Citius Pharmaceuticals is the larger company: $1.5M of revenue in its latest quarter (Q3 FY26) against $1.5M for Vistagen Therapeutics (Q1 FY27). Citius Pharmaceuticals is more profitable, with an operating margin of -785.4% against -904.3%.

Citius Pharmaceuticals vs Vistagen Therapeutics, latest quarterCitius Pharmaceuticals vs Vistagen Therapeutics, latest quarterCitius Pharmaceuticals (CTXR)Vistagen Therapeutics (VTGN)Revenue$1.5M$1.5MOperating margin-785.4%-904.3%Net margin-797.9%-882.8%

Where the money goes: CTXR and VTGN

Citius Pharmaceuticals (CTXR) · Q3 FY26

Citius Pharmaceuticals, Q3 FY26: revenue $1.5M, operating margin -785.4%, net loss $11.9M, operating cash flow −$8.7M. The chart follows the revenue to costs, profit and cash.

Vistagen Therapeutics (VTGN) · Q1 FY27

Vistagen Therapeutics, Q1 FY27: revenue $1.5M (+505% year over year), operating margin -904.3%, net loss $13.0M, operating cash flow −$14.7M. The chart follows the revenue to costs, profit and cash.

Citius Pharmaceuticals (CTXR)Vistagen Therapeutics (VTGN)
Latest quarterQ3 FY26Q1 FY27
Revenue$1.5M$1.5M
Revenue growth, Y/Y—+505%
Operating margin-785.4%-904.3%
Net earnings−$11.9M−$13.0M
Net margin-797.9%-882.8%
Operating cash flow−$8.7M−$14.7M

Questions

Which is bigger, Citius Pharmaceuticals or Vistagen Therapeutics?

Citius Pharmaceuticals is the larger company: $1.5M of revenue in its latest quarter (Q3 FY26) against $1.5M for Vistagen Therapeutics (Q1 FY27).

Is Citius Pharmaceuticals or Vistagen Therapeutics growing faster?

Citius Pharmaceuticals is more profitable, with an operating margin of -785.4% against -904.3%.

More: Citius Pharmaceuticals earnings · how Citius Pharmaceuticals makes money · Vistagen Therapeutics earnings · how Vistagen Therapeutics makes money

From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.